World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
80
Citations
27787
World Ranking
16985
National Ranking
679

Diana Giannarelli publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Diana Giannarelli sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 804 publications — 87th percentile

87% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Diana Giannarelli D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Diana Giannarelli sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 80 D-Index — 16th percentile

16% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Diana Giannarelli is affiliated with Sapienza University of Rome in Italy and has made significant contributions in the field of Medicine, with a particular focus on Oncology. Their research spans various subfields including Oncology, Pulmonary and Respiratory Medicine, Genetics, Reproductive Medicine, and Surgery.

Their work covers key topics such as:

  • Cancer Immunotherapy and Biomarkers
  • Ovarian cancer diagnosis and treatment
  • Chronic Lymphocytic Leukemia Research
  • Endometrial and Cervical Cancer Treatments
  • SARS-CoV-2 and COVID-19 Research
  • Lung Cancer Treatments and Mutations
  • CAR-T cell therapy research

Frequent co-authors collaborating with Diana Giannarelli include:

  • Giovanni Scambia
  • Anna Fagotti
  • Paolo A. Ascierto
  • Emilio Bria
  • Alessandra Fabi

Their research has been published across notable venues such as:

  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • Journal of Clinical Oncology
  • Cancers
  • ESMO Open

Some recent papers authored or co-authored by Diana Giannarelli include:

  • Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial, 2022, Journal of Clinical Oncology
  • Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine, 2021, EClinicalMedicine
  • Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution, 2021, Journal of Hematology & Oncology
  • Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL), 2020, Leukemia
  • FGFR2 fusion proteins drive oncogenic transformation of mouse liver organoids towards cholangiocarcinoma, 2021, Journal of Hepatology

Best Publications

  • Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

    Pierluigi Benedetti Panici;Stefano Basile;Francesco Maneschi;Andrea Alberto Lissoni

  • Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical Trial

    Pierluigi Benedetti Panici;Angelo Maggioni;Neville Hacker;Fabio Landoni

  • Neoadjuvant Chemotherapy and Radical Surgery Versus Exclusive Radiotherapy in Locally Advanced Squamous Cell Cervical Cancer: Results From the Italian Multicenter Randomized Study

    Pierluigi Benedetti-Panici;Stefano Greggi;Alessandro Colombo;Mariangela Amoroso

  • Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab

    Mariaelena Capone;Diana Giannarelli;Domenico Mallardo;Gabriele Madonna

  • Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

    Luana Calabrò;Aldo Morra;Ester Fonsatti;Ornella Cutaia

  • Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

    Luisa Carbognin;Sara Pilotto;Michele Milella;Vanja Vaccaro

  • Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy.

    Antonio M Grimaldi;Ester Simeone;Diana Giannarelli;Paolo Muto

  • Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab.

    P.F. Ferrucci;P.A. Ascierto;J. Pigozzo;M. Del Vecchio

  • Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features

    Francesca R. Mauro;Robert Foa;Raffaella Cerretti;Diana Giannarelli

  • Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.

    Francesca R. Mauro;Robert Foa;Robert Foa;Diana Giannarelli;Diana Giannarelli;Iole Cordone;Iole Cordone

  • Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response

    A. Pace;A. Vidiri;E. Galiè;M. Carosi

  • Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

    Anna Maria Di Giacomo;Paolo A. Ascierto;Lorenzo Pilla;Mario Santinami

  • Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma

    Ester Simeone;Giusy Gentilcore;Diana Giannarelli;Antonio M. Grimaldi

  • Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial

    F. Cognetti;E. M. Ruggeri;A. Felici;M. Gallucci

  • Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.

    Luana Calabrò;Aldo Morra;Diana Giannarelli;Giovanni Amato

  • Vitamin E neuroprotection for cisplatin neuropathy: A randomized, placebo-controlled trial

    A. Pace;D. Giannarelli;E. Galiè;A. Savarese

  • Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients

    P F Ferrucci;S Gandini;A Battaglia;S Alfieri

  • Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.

    P G Natali;C V Hamby;B Felding-Habermann;B Liang

  • Prevention of VTE in orthopedic surgery patients

    Federico Spandonaro;Rossella Letizia Mancusi;Lorenzo Terranova;Diana Giannarelli

  • Neoadjuvant C hemotherapy a nd R adical S urgery V ersus Exclusive R adiotherapy i n L ocally A dvanced S quamous C ell Cervical C ancer: R esults F rom t he I talian M ulticenter Randomized S tudy

    Pierluigi Benedetti-Panici;Stefano Greggi;Alessandro Colombo;Mariangela Amoroso

Frequent Co-Authors

Francesco Cognetti
Francesco Cognetti Sapienza University of Rome
Michele Maio
Michele Maio University of Siena
Michele Milella
Michele Milella University of Verona
Paolo A. Ascierto
Paolo A. Ascierto National Institutes of Health
Marcella Mottolese
Marcella Mottolese IRCCS Regina Elena Institute
Giampaolo Tortora
Giampaolo Tortora University of Verona
Gennaro Ciliberto
Gennaro Ciliberto Magna Graecia University
Giuseppe Palmieri
Giuseppe Palmieri National Academies of Sciences, Engineering, and Medicine
Ugo De Giorgi
Ugo De Giorgi University of Salento
Manlio Ferrarini
Manlio Ferrarini University of Genoa

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are interested in healthcare careers beyond a traditional MD pathway, a variety of online degree programs are available in the USA. Many registered nurses pursue advanced qualifications to boost their skills and marketability. For example, online rn to bsn programs no clinicals allow nurses to earn a Bachelor’s degree without the need for additional clinical placements, making these programs more accessible and flexible.

For those looking to advance further, doctoral-level programs in nursing are also available online. Some may choose short dnp programs designed for experienced nurses seeking to become clinical experts or move into leadership roles quickly. Meanwhile, others might look for dnp programs that are renowned for being manageable while still offering rigorous training and quality accreditation.

Aspiring nurses who are eager to join the workforce rapidly can consider fast-track diploma pathways like the 6 month lpn program, which provide a quicker route to licensure and employment in practical nursing roles. Each pathway has unique requirements, timeframes, and outcomes, offering candidates a range of academic and career options in the medical field.

Best Scientists Citing Diana Giannarelli

Trending Scientists

Recently Published Articles